Manus received an additional $15 million award to expand its partnership with HHS Administration for Strategic Preparedness and Response's Industrial Base Management and Supply Chain Office (IBMSC) to enable domestic production of shikimic acid.
Public source
Publisher name
Public post
We’re laying the foundation for a more resilient supply of essential medicines in the United States as construction advances on a new building at our Augusta BioFacility…
Company
Manus
Accelerating the Transition to BioAlternatives
- Industry
- Biotechnology Research
- Location
- Boston, US
- Company size
- 51–200 employees
About Manus
Manus is the world’s leading bioalternatives scale-up platform. We work with companies across industries and value chains to accelerate the transition to bioalternatives – better performing and more sustainable versions of complex molecules traditionally sourced from plants, animals, or fossil fuels. Our platform is proven to work across scales, bridging the Valley of Death between lab and manufacturing more efficiently and more reliably to deliver the benefits of biomanufacturing, today.
See moreLatest activity
Latest activity from Manus
8 signals
Research & Knowledge
Manus and The University of Texas at Austin completed a BioMADE-sponsored program to improve product recovery in biomanufacturing by addressing a key downstream processing bottleneck.
Partnerships
Manus announced the construction of its Augusta BioFacility in partnership with HHS Administration for Strategic Preparedness and Response's Industrial Base Management and Supply Chain Office (IBMSC) under the Defense Production Act Title III program.
Operations & Supply
Manus is constructing a new building at its Augusta BioFacility to bring new cGMP capabilities to the site, combining biomanufacturing and flow chemistry under one roof to onshore U.S. production of artemisinin.
Discover more
Similar signals
Similar public activity from other companies.
Partnerships
Emergent BioSolutions
Emergent BioSolutions was awarded a contract modification valued at approximately $24 million from the U.S. government to supply CYFENDUS.
Partnerships
iPROOF
iPROOF will help bioproduct innovators bridge the gap between lab-based innovations and viable commercialization beginning in early 2027.
Partnerships
BioMADE
BioMADE is advancing more accessible, reproducible, and decentralized bioproduction through a new BioMADE project with Roke Biotechnologies and Duke University.
Partnerships
Ennolys by Lesaffre
Ennolys by Lesaffre is expanding its dedicated CDMO services to become a strategic partner in de-risking and accelerating sustainable biotech innovation.
Partnerships
Earthia Bio